Writing Styles – Let’s hear it for…..the Tuatara
Those of you know me well (including those who wish they didn’t) will know that my heart and roots belong in New Zealand. Fortified by a large quantity of excellent…
How do we really know what people want in terms of healthcare?
It is assumed that people make, or should make, rational choices based on self-interest. For conventional health economic evaluations, self-interest is approximated by individual preferences, such as maximum willingness-to-pay (WTP)…
Can China utilise a Value Based Pricing approach much like the UK?
Interview with Dr John Cai, a highly experienced economist and health economist with 20 years’ experience in both China and the US. John is a Senior Health Policy Analyst at the Massachusetts Executive Office of Health and Human Services in the U.S. heor.tv
ISPOR EU 2009: Bringing the Eiffel Tower into Perspective
Getting a drug approval, reimbursement, and access to markets is a long journey, but we are not alone. The focus on this year’s ISPOR EU annual conference was on health technology assessment in different countries. Is an international appraisal system likely in the near future?
‘You say HTA, I say CER’: international perspectives on evidence-based health policy
George Bernard Shaw once described America and England as two countries separated by a common language. Might this also hold true for comparative effectiveness research and health technology assessment? This article highlights several, recently available resources for anyone seeking to understand healthcare systems outside their own country.
2009 brings a move toward ending pharma freebies
By Mary Gabb (mary.gabb@rxcomms.com) January 1, 2009 – typically a day of new beginnings – marked the beginning of the end of SWAG (stuff we all get, or freebies) for…
Drug makers gift disclosures: the ethics issue
By David Woods (david.woods@rxcomms.com) Drug company Eli Lilly has said that it will start disclosing the amounts of money over $500 that it pays to physicians – and other firms…
Direct-to-Consumer Advertising – in Europe?
By Mary Gabb (mary.gabb@rxcomms.com ) Since 1996, DTCA has existed only in the USA and New Zealand , but recent declarations from the European Commission (EC) suggest that the rules…
‘Big box’ companies and public health
By David Woods (david.woods@rxcomms.com) Whether it’s because of a shortage of primary care physicians, impatience at the length of time it takes to see one, or simply increasing costs, the…
Regulating DTC ads – Are we attempting to herd cats?
By Mary Gabb (mary.gabb@rxcomms.com) In a previous issue of HOC , we outlined some of the commonly expressed pros and cons of direct-to-consumer advertising (DTCA), which is currently allowed only…